Lucid Finally Got Paid by Medicare — and the Stock Fell 58%
The reimbursement breakthrough arrived through a Texas contractor and a claim-by-claim pathway, not the long-promised MolDx LCD. The equity is still priced as an option, not a business.
LUCD · Earnings Call · 2026-11-12
The win that isn't the one they sold
For roughly a year, Lucid Diagnostics ran a one-variable story: wait for the MolDx local coverage determination. On the March call the CEO was categorical — “Medicare is coming. It is a matter of when, not if.” — Dr. Lishan Aklog, Chairman and CEO · 2026-03-26 By November 2025 the company was guiding investors to a draft LCD by year-end. By May and again by August, the draft was still stuck in a CMS administrative backlog. Then this quarter Lucid solved the problem sideways. The Medicare contractor with jurisdiction over its Texas laboratory — Novitas, which sits outside the MolDx program — began adjudicating Medicare claims as reasonable and necessary in late September and paying them in October. The formal term is claim-by-claim adjudication, and management is right that most Medicare claims are decided this way. “For the first time, Medicare beneficiaries nationwide have fully reimbursed access to our groundbreaking EsoGuard test.” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-12 The logical consequence is that the MolDx LCD — the single obsession of four prior calls — is now optional. It still ranks near the top of the company's keyword set this quarter, but it is discussed as a parallel track and a backlog artifact rather than the gating item. That is the real news buried under the headline: a company that spent years waiting on one regulator quietly stopped needing it. The questions that followed were about Medicare population targeting and sales-force productivity, not about Washington.Recognition is the actual business story
The revenue line is where the breakthrough confronts accounting. McGrath laid out the arithmetic plainly:That is the whole thesis in two numbers. The quarter itself recognized $1.2 million against roughly $7.9 million of billable value — about 15% realization, unchanged in structure if better in quality (average insurance allowable rose to $1,700 from $1,420). The sequential revenue decline was almost entirely direct contracting timing: 517 contracted tests in Q2 versus 60 in Q3. Medicare changes this because Novitas claims are now "predictable enough to consistently recognize upon report delivery," converting a cash-basis-like model into something closer to accrual for half the addressable market. The volume datapoint is the one that matters most: more than 1,800 tests in October alone, a monthly record, against 2,870 for the entire third quarter. Medicare volume in October already hit ~70% of the full prior quarter. Receivables to revenue has already climbed to roughly 72% — visible evidence that the recognition change is underway.we have now performed more than 50,000 EsoGuard tests since inception, reflecting more than $140 million billings. Against approximately $16 million collected to date.